These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25241106)

  • 21. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
    Ramanathan R; Rasmussen MR; Gerstmann DR; Finer N; Sekar K;
    Am J Perinatol; 2004 Apr; 21(3):109-19. PubMed ID: 15085492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome.
    Malloy CA; Nicoski P; Muraskas JK
    Acta Paediatr; 2005 Jun; 94(6):779-84. PubMed ID: 16188788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicenter, randomized, double-blind trial of a new porcine surfactant in premature infants with respiratory distress syndrome.
    Rebello CM; Precioso AR; Mascaretti RS;
    Einstein (Sao Paulo); 2014; 12(4):397-404. PubMed ID: 25628188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurodevelopmental outcomes of very low birth weight preterm infants treated with poractant alfa versus beractant for respiratory distress syndrome.
    Eras Z; Dizdar EA; Kanmaz G; Guzoglu N; Aksoy HT; Altunkaya GB; Canpolat FE; Dilmen U
    Am J Perinatol; 2014 Jun; 31(6):463-8. PubMed ID: 23884719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poractant alfa versus bovine lipid extract surfactant: prospective comparative effectiveness study.
    Lemyre B; Lacaze-Masmonteil T; Shah PS; Bodani J; Doucette S; Dunn M; Louis D; Monterrosa L; Mukerji A; Schmölzer GM; Singh B; Wong J; Ye XY; Offringa M
    J Perinatol; 2022 Apr; 42(4):468-475. PubMed ID: 35177795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surfactant without intubation in preterm infants with respiratory distress: first multi-center data.
    Kribs A; Härtel C; Kattner E; Vochem M; Küster H; Möller J; Müller D; Segerer H; Wieg C; Gebauer C; Nikischin W; Wense Av; Herting E; Roth B; Göpel W
    Klin Padiatr; 2010; 222(1):13-7. PubMed ID: 20084586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Choosing a right surfactant for respiratory distress syndrome treatment.
    Ramanathan R
    Neonatology; 2009; 95(1):1-5. PubMed ID: 18832858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.
    Bassler D
    Neonatology; 2015; 107(4):358-9. PubMed ID: 26044104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group.
    Long W; Corbet A; Cotton R; Courtney S; McGuiness G; Walter D; Watts J; Smyth J; Bard H; Chernick V
    N Engl J Med; 1991 Dec; 325(24):1696-703. PubMed ID: 1944470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poractant alfa versus bovine lipid extract surfactant for infants 24+0 to 31+6 weeks gestational age: A randomized controlled trial.
    Lemyre B; Fusch C; Schmölzer GM; Rouvinez Bouali N; Reddy D; Barrowman N; Huneault-Purney N; Lacaze-Masmonteil T
    PLoS One; 2017; 12(5):e0175922. PubMed ID: 28472058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surfactant therapy in neonates with respiratory deterioration due to pulmonary hemorrhage.
    Pandit PB; Dunn MS; Colucci EA
    Pediatrics; 1995 Jan; 95(1):32-6. PubMed ID: 7770305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On "A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants" (Am J Perinatol 2004;21:109-120).
    Bancalari E
    Am J Perinatol; 2004 Jul; 21(5):307-9. PubMed ID: 15232767
    [No Abstract]   [Full Text] [Related]  

  • 33. Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: final analysis of a multicenter, double-blind, randomized trial and comparison with similar trials. The Surfactant-TA Study Group.
    Fujiwara T; Konishi M; Chida S; Okuyama K; Ogawa Y; Takeuchi Y; Nishida H; Kito H; Fujimura M; Nakamura H
    Pediatrics; 1990 Nov; 86(5):753-64. PubMed ID: 2235230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical course of premature infants intubated in the delivery room, submitted or not to porcine-derived lung surfactant therapy within the first hour of life.
    Lefort S; Diniz EM; Vaz FA
    J Matern Fetal Neonatal Med; 2003 Sep; 14(3):187-96. PubMed ID: 14694974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo comparison between poractant alfa and the new generation synthetic surfactant CHF5633.
    Ricci F; Murgia X; Razzetti R; Pelizzi N; Salomone F
    Pediatr Res; 2017 Feb; 81(2):369-375. PubMed ID: 27973472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early respiratory management of respiratory distress syndrome in very preterm infants and bronchopulmonary dysplasia: a case-control study.
    Te Pas AB; Lopriore E; Engbers MJ; Walther FJ
    PLoS One; 2007 Feb; 2(2):e192. PubMed ID: 17285145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants.
    Rastogi A; Akintorin SM; Bez ML; Morales P; Pildes RS
    Pediatrics; 1996 Aug; 98(2 Pt 1):204-10. PubMed ID: 8692619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nasal intermittent positive pressure ventilation after surfactant treatment for respiratory distress syndrome in preterm infants <30 weeks' gestation: a randomized, controlled trial.
    Ramanathan R; Sekar KC; Rasmussen M; Bhatia J; Soll RF
    J Perinatol; 2012 May; 32(5):336-43. PubMed ID: 22301528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Observational study to compare the clinical efficacy of the natural surfactants Alveofact and Curosurf in the treatment of respiratory distress syndrome in premature infants.
    Proquitté H; Dushe T; Hammer H; Rüdiger M; Schmalisch G; Wauer RR
    Respir Med; 2007 Jan; 101(1):169-76. PubMed ID: 16698258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized clinical trial comparing two natural surfactant preparations to treat respiratory distress syndrome.
    Hammoud M; Al-Kazmi N; Alshemmiri M; Thalib L; Ranjani VT; Devarajan LV; Elsori H
    J Matern Fetal Neonatal Med; 2004 Mar; 15(3):167-75. PubMed ID: 15280142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.